The Institute for Technology Assessment’s (ITA) mission is to conduct health outcomes research to guide the development, evaluation, and utilization of medical technologies that improve the quality and cost-effectiveness of medical care
Who are we?
We are physicians and methodologic experts from diverse fields and we find where healthcare is valuable. Our research aims to optimize disease treatment and prevention, quality of life, and cost-effectiveness of care. The ITA includes individuals with training and expertise in the core disciplines of biostatistics, epidemiology, economics, decision science, health-related quality of life measurement, outcomes analysis, and health care policy.
What do we do at the ITA?
We synthesize currently available data from myriad sources to develop mathematical models that answer big-ticket public health questions when clinical trials are not feasible
We work in a collaborative team
The ITA is known for outcomes research in cancer (colorectal, lung, esophageal & thyroid) and several new research projects were initiated in the last five years that aim at informing policies to address the opioid epidemic (in collaboration with the Food and Drug Administration), global hepatitis C elimination (in collaboration with the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO)), and more recently, COVID-19 mitigation response in the U.S.
Workshop on Generative AI for HEOR and Market Access
Hosted by the MGH Institute for Technology Assessment, Harvard Medical School
Dates: Sept 12: 9am-5pm, Sept 13: 9am-12:30pm
Location: MGB Assembly Row, 399 Revolution Drive, Somerville, MA 02145
Join us for an immersive and practical workshop designed to help you understand and utilize generative AI in Health Economics and Outcomes Research (HEOR) and Market Access. This workshop will provide a comprehensive overview of the current landscape, practical use cases, and hands-on demonstrations, ensuring you leave with actionable insights and skills.
Designed for executives and managers from life sciences sector, this workshop will cover:
ITA in the News
Costs of Alcohol-Associated Liver Disease Will Double by 2040
Excited about new diet drug? This procedure seems better choice.
